Quick Facts

• Condition Supported: Irritable Bowel Syndrome (IBS)
• Symptom Relief: Abdominal pain and cramps
• Additional Use: Management of similar gastrointestinal spasms

---

What Meva Treats: Main Uses and Benefits

Meva (mebeverine hydrochloride) is designated for the symptomatic management of conditions related to the lower gastrointestinal tract. Its primary purpose is to provide relief from the uncomfortable symptoms associated with Irritable Bowel Syndrome (IBS).

The medication is indicated to help with abdominal pain and cramping that can occur with IBS. It may also contribute to the reduction of symptoms associated with other gastrointestinal issues that involve intestinal muscle spasms, such as chronic irritable colon, mucous colitis, and spastic colitis.

In the context of IBS, Meva supports the mitigation of painful spasms, helping to manage the discomfort that can be experienced in the gut. Treatment is typically initiated to address these specific symptoms, allowing for overall symptom control as part of a comprehensive management plan.

This section outlines the official population eligibility criteria for Meva (Mebeverine hydrochloride), based strictly on regulatory prescribing information.

Eligibility Scope

Category	Entity/Rule
Populations for whom use is allowed	Adults (including the elderly)
Populations for whom use is not recommended	Children and adolescents below 18 years
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance or excipients

---

Regulatory Eligibility Rules

Absolute Prohibitions

Use is contraindicated for patients with a known hypersensitivity to mebeverine hydrochloride. It is also prohibited for individuals with rare hereditary problems of galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption, as the formulation contains lactose.

Age and Physiological Status

Use in children and adolescents below 18 years is not recommended due to insufficient official data on safety and efficacy in this pediatric population. The medicine is not recommended during pregnancy and should not be used during breast-feeding due to limited or unknown data on safety and excretion in human milk.

Organ Function

While no specific dosage adjustment is deemed necessary for elderly, renal, or hepatic impaired patients based on post-marketing data, individuals with existing liver or kidney problems should consult a healthcare professional prior to use. Official regulatory documents primarily state that efficacy and safety have only been evaluated in adults.

Interactions with other medicines and products

Mebeverine hydrochloride (Meva) has a minimal interaction profile as documented in official government regulatory sources. The regulatory assessment of the medicine’s interaction risk is defined primarily by the absence of known interactions with other medicinal products.

Documented Interaction Patterns

Interaction Type	Regulatory Position
Drug–Drug Interactions	No formal interactions with other medicines are known or documented in official prescribing information.
Metabolic Interactions	Metabolism occurs via esterase hydrolysis; no specific interactions involving CYP enzymes or drug transporters are documented as clinically significant.
Contraindicated Combinations	No drug–drug combinations are formally classified as contraindicated based on an interaction risk in the product label.
Alcohol (Ethanol)	Formal regulatory studies have confirmed the absence of an interaction with ethanol.

Interaction-Related Considerations

The official regulatory label asserts that the mebeverine interaction profile does not necessitate dosage adjustments for co-administration with other medicines. Additionally, no specific risks or altered interaction profiles have been identified from post-marketing data that would require unique cautions for the elderly population or for patients with renal or hepatic impairment. Consequently, there are no mandatory timing rules documented that require separation of administration from other substances due to a pharmacokinetic interaction.

How Meva Works: A Mechanistic Overview

Disrupting Parasite Microtubule Structure

Meva's primary function is to inhibit the polymerization of beta-tubulin in parasitic cells, targeting the core structures required for cell integrity and internal transport. This molecular action leads directly to the loss of cellular structural integrity and functional impairment, initiating structural and metabolic failure.

Inhibiting Nutrient Uptake and Energy Production

The structural damage caused by Meva cascades into critical metabolic pathways, most notably by blocking the parasite's ability to absorb glucose and other nutrients. This mechanism depletes energy stores (ATP), contributing to degenerative changes in the parasite's organelles and resulting in cessation of cellular function.

Selective Action and Peripheral Focus

Meva demonstrates high selectivity for parasitic tubulin over host tubulin, and its poor systemic absorption results in the mechanism being predominantly active in the peripheral areas where the target organisms reside. This dual selectivity contributes to a limited effect on host physiological systems.

Administration and Dosage Schedules

Official instructions establish distinct daily dosing regimens. The medicine is taken preferably 20 minutes before meals to align its effect with gastrointestinal activity.

Dosage Form	Strength	Frequency	Administration Constraint
Film-coated Tablet	135 mg	Three times per day (TID)	Maximum of three tablets per day
Modified-release Capsule	200 mg	Twice per day (BID)	Do not crush or chew

---

Procedural Instructions and Use Patterns

All forms must be swallowed whole with a sufficient amount of water; specifically, the modified-release capsules must not be broken, crushed, or chewed to preserve their prolonged-release mechanism. The duration of use is generally not limited, indicating that the course may be continued as necessary.

Dose Management and Special Populations

If the desired therapeutic effect is sustained over several weeks, the dose may be gradually reduced. Should a dose be missed, the next dose should be taken at the regularly scheduled time, and a double dose must not be taken to compensate. Meva is not recommended for use in children and adolescents below 18 years due to insufficient data. No dosage adjustment is deemed necessary for older adults or in cases of renal or hepatic impairment.

Research Evidence / Overview of Studies for Meva

---

Evidence for Use in Irritable Bowel Syndrome (IBS) and Functional Bowel Disorders

Meva was evaluated in research settings exploring how symptoms change over time in people with Irritable Bowel Syndrome (IBS) and other conditions characterized by functional imbalance in the gut. The core research used to evaluate Meva involves Randomized Controlled Trials (RCTs). These short-term studies were used to compare Meva against a placebo (an inactive dummy treatment) to monitor how symptoms changed in the observed populations. Research primarily monitored patient-reported outcomes describing perceived discomfort, such as measurements of change in the intensity and frequency of abdominal pain and the overall assessment of global symptom status.

Studies report how symptoms evolved in the observed populations, and research highlights changes measured during the study period for outcomes related to physical discomfort. Findings describe patterns observed in the studies, particularly regarding changes measured in pain levels and bowel function. Studies focusing on episodes where symptoms become more noticeable generally monitored responses over defined time intervals, with most controlled trials lasting between four and eight weeks.

---

Comparing Meva to Placebo and Other Treatments

Research has examined Meva against placebo in individuals with conditions characterized by fluctuating or episodic manifestations. The comparison with an inactive placebo is a standard feature of research for isolating potential patterns of effect. In systematic reviews that pool the data from many separate trials, findings varied across systematic reviews. Some individual studies reported patterns of greater change in abdominal pain measures compared to those who received placebo. However, when the data from numerous controlled trials are combined, research exploring short-term symptom changes often reports no statistically significant difference between Meva and placebo for the primary outcome of overall global symptom improvement.

---

Long-Term Studies and Durability of Effect

The majority of high-quality, controlled evidence is derived from short-term trials with follow-up durations that were limited, often lasting only one to three months. Evidence for how symptoms evolve over extended time periods is less extensive. While some observational settings evaluating daily-life functioning have monitored patient responses for up to a year, these are typically not controlled trials. Therefore, long-term effects are not fully established, and there is limited information for how symptoms are managed or how durability of response is maintained over many months or years.

---

Evidence in Specific Patient Populations

Meva was evaluated mostly in adults with conditions involving periods of heightened symptoms. Specific research exploring its use has also been conducted in adolescents (aged 12 to 18) diagnosed with IBS or functional abdominal pain not otherwise specified. For other patient populations, such as older adults or individuals with multiple concurrent health issues (comorbidities), data for certain groups remain insufficient. Clinical trial evidence specifically for the use of Meva during pregnancy or breastfeeding is also limited.

---

Research Limitations and Areas of Uncertainty

A key limitation is the heterogeneity of the research: differences in study design, the specific diagnostic criteria used, and the definitions of a successful patient outcome (a "responder") mean that evidence quality varies across studies. This variability makes combining and interpreting results challenging, contributing to the mixed findings seen in pooled analyses.

While Meva was studied in the context of core IBS symptoms, the evidence underscores that the certainty remains low regarding consistent statistical differences from placebo in some key outcome measures, highlighting areas where research is ongoing and more robust, consistent data are still needed. Furthermore, results apply only to the populations studied, meaning research does not determine whether an individual will respond similarly.

Key Studies & References

1. The Efficacy of Mebeverine in the Treatment of Irritable Bowel Syndrome—A Systematic Review (Newer systematic review, more positive findings, addresses heterogeneity)
2. Public Assessment Report Scientific discussion Mebeverine HCl Aurobindo Retard 200 mg modified release capsules, hard (Regulatory document, indication and population)

Common questions about Meva (FAQ)

Q: Is Meva a type of antibiotic or a different kind of medicine?

Meva is classified by official health organizations as a musculotropic antispasmodic agent for the management of functional gastrointestinal spasm. This classification means it is intended to relax the smooth muscles in the gut. It is not an antibiotic, which is a type of medicine specifically used to treat bacterial infections.

---

Q: What does the term 'mechanism of action' mean for Meva in simple terms?

The mechanism of action describes how a medicine works inside the body at a cellular level. Official documents explain that Meva's primary function is to cause smooth muscle relaxation directly on the wall of the gastrointestinal tract. This selective action is intended to help relieve muscle contractions or spasms in the bowel.

---

Q: Can people with a history of heart problems use Meva?

Official labeling advises that individuals who have pre-existing heart conditions, such as angina, should consult with a healthcare professional before starting Meva. Regulatory information advises consulting a healthcare professional to ensure all factors related to a patient’s health history are considered.

---

Q: Why do official documents state that Meva should not be used in people with kidney issues?

Regulatory information advises individuals with existing kidney problems to consult a healthcare professional prior to using Meva. It is noted that based on available post-marketing data, no specific dosage adjustment is typically deemed necessary for people with renal impairment. Consultation with a healthcare professional is noted to ensure the medicine’s eligibility and use conditions are appropriate.

---

Q: Does Meva help with symptoms right away, or does it take time? / How quickly do the benefits of Meva usually become noticeable in studies?

Meva is described as a treatment that is intended to act rapidly. Authoritative health sources indicate that the medicine generally starts to work after about one hour following administration. Individual responses may vary, and research evidence primarily focuses on symptom change over the duration of the study.

---

Q: Is it normal to feel tired or dizzy when first starting Meva?

Official prescribing documents list tiredness (fatigue) and dizziness as reported adverse effects that have been spontaneously experienced by some patients. These are documented in the safety profile alongside other reported effects.

---

Q: Can Meva affect sleep patterns, like causing insomnia or making me drowsy?

Regulatory documents list difficulty sleeping (insomnia) as a reported adverse effect. If changes in sleep patterns or drowsiness occur, patients are advised to consult a healthcare provider.

---

Q: Does Meva interact with common pain relievers like ibuprofen or acetaminophen?

Official drug information states that Meva has a minimal interaction profile. It is not known to interact with most other prescription medicines or commonly used over-the-counter painkillers, such as ibuprofen or acetaminophen.

---

Q: Are there any specific vitamins, supplements, or herbal products that should be avoided while taking Meva?

Official regulatory sources state that there is insufficient information to confirm that complementary medicines or herbal remedies are safe to take alongside Meva. Official guidelines note that all supplements, vitamins, or herbal products being used should be disclosed to a healthcare provider.

---

Q: What happens if I accidentally miss taking Meva one day?

If one or more doses are missed, official instructions advise that the patient should continue with the next dose as originally scheduled. It is explicitly stated that the missed dose should not be taken in addition.

---

Q: Can Meva change my appetite?

Regulatory documents list loss of appetite as a reported adverse effect that has occurred in some people using Meva. This is included in the medicine's documented safety information.

---

Q: Is there any public research available on Meva's long-term safety profile?

Regulatory documents acknowledge that the majority of high-quality evidence is derived from short-term clinical trials. Evidence for long-term safety over extended periods remains less extensive, and for chronic use, it is noted that additional adverse effects may occur under long-term treatment.

---

Q: Does Meva have any warnings about driving or operating machinery?

Official regulatory information specifies that Meva is not likely to affect a patient's ability to drive or safely use any tools or machinery. However, if adverse effects like dizziness occur, a patient's ability to drive or use machinery may be affected.

---

Q: Can I consume alcohol in moderation while using Meva?

Formal regulatory studies confirmed the absence of an interaction with ethanol (alcohol). Official documents state that you can drink alcohol while taking the medicine.

---

Q: What is the most frequently reported mild side effect in people taking Meva?

Regulatory documents classify reported adverse reactions as having a Frequency Not Known. This means that a precise incidence rate or an estimate of which effects are 'most frequent' cannot be calculated from the available surveillance data.

The official labeling for Meva (mebeverine hydrochloride) specifies strict conditions to maintain product stability and ensure environmental protection during disposal.

---

Required Storage and Handling

• Temperature and Environment: Store this medicine at a temperature not greater than 30°C and below 30°C. The product must be stored in a dry place, protected from light, and must not be refrigerated or frozen.
• Packaging and Child Safety: Keep the medicine in its original package. Do not use it after the expiry date. All forms of this medicine must be kept strictly out of the sight and reach of children.

---

Official Disposal Rules

Do not throw away any medicines via wastewater or household waste. Disposal must be managed as pharmaceutical waste; you must ask your pharmacist how to dispose of medicines no longer required in accordance with local regulations.